Osteopontin expression is an independent factor for poor survival in oral squamous cell carcinoma: A computer-assisted analysis on TMA sections

Journal of Oral Pathology and Medicine

Volumn 42, Issue 8, 2013, Pages 620-626

  Avirović, Manuela ^a   Matušan Ilijaš, Koviljka ^a   Damante, Giuseppe ^b   Fabrro, Dora ^c   Cerović, Robert ^d   Juretić, Mirna ^d   Grahovac, Blaženka ^a   Jonjić, Nives ^a   Lučin, Ksenija ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF UDINE   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d KBC RIJEKA   (Croatia)

Author keywords

Osteopontin; Squamous cell carcinoma of head and neck; Tissue array analysis

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

OSTEOPONTIN; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK; TISSUE ARRAY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OSTEOPONTIN; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84883539709     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12055     Document Type: Article

References (35)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-900.
2. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055-61.
3. Bellahcene A, Castronovo V, Ogbureke K, Fisher LW, Fedarko NS. Small Integrin-Binding Ligand N-linked Glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008; 8(3): 212-26.
4. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12.
5. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res 2011; 49: 160-72.
6. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27.
7. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol 2006; 94: 325-31.
8. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007; 6: 18.
9. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79: 127-32.
10. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-21.
11. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98: 119-27.
12. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999; 160: 1269-73.
13. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-9.
14. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebocontrolled trial. Lancet Oncol 2005; 6: 757-64.
15. Chien CY, Su CY, Chuang HC, et al. Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck 2008; 30: 776-81.
16. Chien CY, Su CY, Chuang HC, et al. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009; 45: 798-802.
17. Ogbureke KU, Nikitakis NG, Warburton G, et al. Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer. Oral Oncol 2007; 43: 920-32.
18. Ogbureke KU, Weinberger PM, Looney SW, Li L, Fisher LW. Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget 2012; 3(3): 286-98.
19. Barnes L, Eveson JW, Reichart P, Sidransky D. WHO Classification of tumours, Pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005: 165.
20. Warren S. The grading of carcinoma of the cervix uteri as checked at autopsy. Arch Pathol 1931; 12: 783-6.
21. Matušan-Ilijaš K, Damante G, Fabbro D, et al. Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract 2011; 207: 104-10.
22. Cook AC, Tuck AB, McCarthy S, et al. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 2005; 43: 225-36.
23. Devoll RE, Li W, Woods KV, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 1999; 28: 97-101.
24. Matsuzaki H, Shima K, Muramatsu T, et al. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007; 36: 30-4.
25. Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 2007; 34: 343-6.
26. Petrik D, Lavori PW, Cao H, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006; 24: 5291-7.
27. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59-67.
28. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
29. Muramatsu T, Shima K, Ohta K, et al. Inhibition of osteopontin expression and function in oral cancer cell lines by antisense oligonucleotides. Cancer Lett 2005; 217: 87-95.
30. Kon S, Maeda M, Segawa T, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000; 77: 487-98.
31. Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011; 13: 15.
32. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-15.
33. Hsieh YH, Margaret Juliana M, Ho KJ, et al. Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells. Int J Cancer 2012; 131: 322-33.
34. Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery 2006; 140: 132-40.
35. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 2007; 102: 912-24.